Thomas Hecht is listed as a director on 2 SEC Form D filings by 2 issuers between Apr 2019 and Apr 2023: Verseon Corp (Fremont, CA — pharmaceuticals — 2019; $11.8M reported sold to 28 investors) and Encentrio Therapeutics, Inc. (San Francisco, CA — biotechnology — 2023; $400K reported sold to 1 investors).
What this means 2 separate companies raised money with this person listed as director, over about 4 years. Across those companies the filings report $12.2M sold in total.
Listed alongside Adityo Prakash (1 shared filing), David Kita (1 shared filing), Eniko Fodor (1 shared filing), George Scangos (1 shared filing), Johanna Friedl-Naderer (1 shared filing) and 4 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Thomas. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — 4 bankruptcy cases matching the name listed in Key records below.
What this means 4 records came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.
We compared 2 public filings for Thomas Hecht and found 3 differences: Form D filed 37 days after the first sale; Same name, different state: "Thomas Hecht" (V8 or A6) is a separate record; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.